17β-Estradiol attenuates diabetic kidney disease by regulating extracellular matrix and transforming growth factor-β protein expression and signaling

Alexis Dixon,Christine Maric
DOI: https://doi.org/10.1152/ajprenal.00079.2007
2007-11-01
Abstract:We previously showed that supplementation with 17β-estradiol (E 2 ) from the onset of diabetes attenuates the development of diabetic renal disease. The aim of the present study was to examine whether E 2 can also attenuate the disease process once it has developed. The present study was performed in nondiabetic and streptozotocin-induced diabetic Sprague-Dawley rats. E 2 supplementation began after 9 wk of diabetes and continued for 8 wk. Diabetes was associated with an increase in urine albumin excretion, glomerulosclerosis, tubulointerstitial fibrosis, renal cortical collagen type I and IV, laminin, plasminogen activator inhibitor-1, tissue inhibitors of metalloproteinase-1 and -2, transforming growth factor (TGF)-β, TGF-β receptor type I and II, Smad2/3, phosphorylated Smad2/3, and Smad4 protein expression, and CD68-positive cell abundance. Decreases in matrix metalloproteinase (MMP)-2 protein expression and activity and decreases in Smad6 and Smad7 protein expression were also associated with diabetes. E 2 supplementation completely or partially attenuated all these changes, except Smad4 and fibronectin, on which E 2 supplementation had no effect. These data suggest that E 2 attenuates the progression of diabetic renal disease once it has developed by regulating extracellular matrix, TGF-β, and expression of its downstream regulatory proteins. These findings support the notion that sex hormones in general, and E 2 in particular, are important regulators of renal function and may be novel targets for the treatment and prevention of diabetic renal disease.
What problem does this paper attempt to address?